Mar 03, 2020
CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free
Feb 27, 2020
CNS Pharmaceuticals to Ring Nasdaq Stock Market Opening Bell on March 3
Feb 04, 2020
AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial
Jan 29, 2020
DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Jan 24, 2020
University Hospitals Seidman Cancer Center Treats Its First Glioblastoma Patient With Genetically Modified Poliovirus
Jan 22, 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Jan 13, 2020
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
Jan 09, 2020
American Brain Tumor Association and Uncle Kory Foundation Announce Partnership to Accelerate Brain Tumor Research
Dec 12, 2019
Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit
Dec 11, 2019
Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit
Dec 11, 2019
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
Dec 09, 2019
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit
Nov 26, 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Nov 25, 2019
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
Nov 25, 2019
Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting
Nov 25, 2019
DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM
Nov 24, 2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 21, 2019
Cancer Drugs and New Therapies for Dangerous Brain Tumors Advancinghl2Financialnewsmedia.com News Commentary
Nov 21, 2019
Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clinical Trial
Nov 20, 2019
Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results